ImmunityBio Inc (NASDAQ: IBRX)’s stock price has soared by 0.61 in relation to previous closing price of 2.47. Nevertheless, the company has seen a loss of -5.51% in its stock price over the last five trading days. businesswire.com reported 2025-04-15 that CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary disease and an EAP for ANKTIVA® (nogapendekin alfa inbakicept-pmln) for the treatment of lymphopenia. Supplemental Biologics License Application (sBLA): In Q1, ImmunityBio completed the submission to the FDA of an sBLA for the use of ANKTIVA plus BCG in BCG-unrespon.
Is It Worth Investing in ImmunityBio Inc (NASDAQ: IBRX) Right Now?
The 36-month beta value for IBRX is at 0.28. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IBRX is 91.80M, and currently, shorts hold a 68.83% of that float. The average trading volume for IBRX on April 21, 2025 was 6.46M shares.
IBRX’s Market Performance
The stock of ImmunityBio Inc (IBRX) has seen a -5.51% decrease in the past week, with a -9.64% drop in the past month, and a -15.48% fall in the past quarter. The volatility ratio for the week is 10.80%, and the volatility levels for the past 30 days are at 10.26% for IBRX. The simple moving average for the past 20 days is -10.65% for IBRX’s stock, with a -35.45% simple moving average for the past 200 days.
Analysts’ Opinion of IBRX
Many brokerage firms have already submitted their reports for IBRX stocks, with H.C. Wainwright repeating the rating for IBRX by listing it as a “Buy.” The predicted price for IBRX in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on March 06, 2025 of the current year 2025.
BTIG Research, on the other hand, stated in their research note that they expect to see IBRX reach a price target of $6. The rating they have provided for IBRX stocks is “Buy” according to the report published on January 10th, 2025.
Piper Sandler gave a rating of “Neutral” to IBRX, setting the target price at $4 in the report published on May 12th of the previous year.
IBRX Trading at -16.42% from the 50-Day Moving Average
After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.40% of loss for the given period.
Volatility was left at 10.26%, however, over the last 30 days, the volatility rate increased by 10.80%, as shares sank -6.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.72% lower at present.
During the last 5 trading sessions, IBRX fell by -3.99%, which changed the moving average for the period of 200-days by -59.14% in comparison to the 20-day moving average, which settled at $2.78. In addition, ImmunityBio Inc saw -2.93% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IBRX
Current profitability levels for the company are sitting at:
- -23.34 for the present operating margin
- 0.69 for the gross margin
The net margin for ImmunityBio Inc stands at -28.05. The total capital return value is set at -1.05.
Based on ImmunityBio Inc (IBRX), the company’s capital structure generated 31.44 points at debt to capital in total, while cash flow to debt ratio is standing at -0.78. The debt to equity ratio resting at -1.03. The interest coverage ratio of the stock is -2.61.
Currently, EBITDA for the company is -264.43 million with net debt to EBITDA at -1.36. When we switch over and look at the enterprise to sales, we see a ratio of 172.88. The receivables turnover for the company is 5.56for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.36.
Conclusion
In conclusion, ImmunityBio Inc (IBRX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
